Cargando…
Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?
A number of trials have studied the value of aromatase inhibitors (AIs) for the adjuvant treatment of early hormone-responsive postmenopausal breast cancer. Three different AIs have been used and they have been compared as initial treatment (two trials) or after 2–3 years of tamoxifen (four trials),...
| Autores principales: | , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2006
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361185/ https://www.ncbi.nlm.nih.gov/pubmed/16434989 http://dx.doi.org/10.1038/sj.bjc.6602964 |